CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 119 enrolled
Drug / intervention
Fluarix/Influsplit SSW 2012-2013biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01607112
NCT01607112Phase 3Completed
CompareCT.gov

A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

GlaxoSmithKline·interventional·Posted May 28, 2012·Updated Sep 7, 2018

In Brief

A Phase 3 clinical trial evaluating Fluarix/Influsplit SSW 2012-2013 for Influenza. Completed, enrolled 119 participants across 4 sites.

Detailed Summary

The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' trivalent influenza vaccine manufactured for the 2012/2013 influenza season administered in adults (18 to 60 years) and in elderly (over 60 years).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 28, 2012
Enrollment StartJul 10, 2012
Primary CompletionJul 31, 2012
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 14.1 years ago

Interventions

Fluarix/Influsplit SSW 2012-2013biological

1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm